Skip to main content
Updated for 2013. Here is the list of current studies. Contact our office at 713-794-0700 for details.
Hepatitis C Research: New Therapies for Patients Previously Treated with Interferon and Ribavirin, and Those Naive to Antiviral Therapy
Opportunities are available to participate in clinical research protocols through Liver Specialists of Texas and Research Specialists of Texas.
Update: New Hepatitis C Drugs Approved: read more
About half of all people with chronic hepatitis C virus (HCV) infection achieve a sustained virological response (SVR) or undetected HCV, with the standard treatment of pegylated interferon plus ribavirin; rates are even lower for patients with difficult-to-treat HCV genotype 1. Researchers have studied various antiviral agents that directly target various stages of the HCV lifecycle”. Namely protease inhibitors have shown promising results.
For patients who have been previously treated with Pegylated Interferon and Ribavirin and have not responded to treatment or have relapsed while on this treatment you may be eligible for some upcoming studies here at the Research Specialists of Texas. These studies will be looking at a new line of treatment in combination with standard therapy called protease inhibitors for patients with Hepatitis C genotype 1. Protease inhibitors prevent the Hepatitis C virus from replicating or producing more of the virus in your system. You cannot get this medication by prescription as it is not yet approved by the FDA and requires participation on current clinical trials. You are not guaranteed treatment with the protease inhibitors as these studies are placebo controlled, meaning you may receive only standard of care treatment and not the protease inhibitor, but a pill that has no medication that resembles the protease inhibitor.
We are looking to enroll participants from now through the winter 2013. To be considered for participation you MUST be considered a non responders or relapser to treatment, in other words patients who have not responded to standard of care treatment are those who have had documented responsiveness to interferon therapy with a 2 log decrease in their viral count after 12 weeks of treatment, but never achieved a negative viral count. Patients who have relapsed while on standard of care treatment are patients who have become virus free or undetected at some point while on treatment, but did not achieve a sustained negative viral response. Patients who have stopped treatment due to side effects or of their own accord, and HAVE responded to treatment, but were not instructed to stop treatment by their physician for one of the reasons above are not eligible.

If you believe you qualify for these studies please contact Dee Wade at Research Specialists of Texas by phone 713 794 0700. All costs associated with the study are paid for by the sponsor of the study.

Obesity and Fatty Liver Disease

Obesity, and all of its related complications, is more serious than most adults in America believe. More than one-third (34.9% or 78.6 million) of U.S. adults are obese. Obesity-related conditions include heart disease, stroke, type 2 diabetes, fatty liver disease, and certain types of cancer, are some of the leading causes of preventable death. We are seeing an increase in the number of young children and adolescents developing obesity, and all of the related complications.

The cost of obesity is staggering, with annual medical cost of obesity exceeding $147 billion in 2008 U.S. dollars. The medical costs for people who are obese were $1,429 higher than those of normal weight.

Dr. Galati and the Liver Specialists of Texas team are dedicated to evaluate, treat, and manage all aspects of obesity and non-alcoholic fatty liver disease (NAFLD and NASH), including the complication of cirrhosis and liver failure. Developing a customized plan of care for each patient they see is their objective.

Liver Transplant Resources

Dr. Galati has been involved in Liver Transplantation since 1989. As Medical Director for the Center for Liver Disease and Transplantation at Houston Methodist Hospital, Dr. Galati has cared for thousands of patients with advanced liver disease. In those with the most severe form of advanced liver disease and cirrhosis, liver transplantation is a life-saving surgery. For more information on liver transplantation, click here.

Indications for liver transplant include:

Online LIVER Second Opinion

  • 1

    From the comfort of your home, without the need to spend additional money on travel, lodging, and food, receive and expert second opinion from the expert physicians at Liver Specialists of Texas

  • 2

    There are five steps in the process of requesting a second opinion. We anticipate the steps will take you about 30-65 minutes to complete.

  • 3

    Have your medical records or those of your loved one on hand as you fill out the medical history questionnaire portion of the online process. The medical history questionnaire is detailed so having medical records to quickly reference will help make the process more efficient.

  • 4

    To start the process of an Online Liver Second Opinion, please fill out the initial contact form and fax back to our office. A representative from our office will call you for additional details.